1.
J Pediatric Infect Dis Soc
; 12(4): 242-245, 2023 Apr 28.
Artículo
en Inglés
| MEDLINE | ID: covidwho-2286626
RESUMEN
This retrospective analysis describes the administration of sotrovimab in 32 children (22 aged 12-16 years old; 10 aged 1-11 years old) who were at high risk of deterioration to severe COVID-19 disease. We provide dosing suggestions and demonstrate the feasibility of sotrovimab use in the younger pediatric population (<12 years old and <40 kg).